Mustang Bio (MBIO) Stock Price, News & Analysis

Company Overview

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Key Stats

• Today's Range: $0.17 to $0.17
• 50-Day Range: $0.17 to $0.31
• 52-Week Range: $0.13 to $1.53
• Volume: 893,867 shs
• Average Volume: 8.29 million shs
• Market Capitalization: $8.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.00
• Consensus Rating: Buy

Mustang Bio Stock Analysis - MarketRank™

Mustang Bio scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Mustang Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Mustang Bio has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mustang Bio are expected to grow in the coming year, from ($0.70) to ($0.39) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mustang Bio is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mustang Bio is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mustang Bio has a P/B Ratio of 17.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.58% of the float of Mustang Bio has been sold short.

Short Interest Ratio / Days to Cover

Mustang Bio has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mustang Bio has recently decreased by 40.36%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mustang Bio does not currently pay a dividend.

Dividend Growth

Mustang Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.58% of the float of Mustang Bio has been sold short.

Short Interest Ratio / Days to Cover

Mustang Bio has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mustang Bio has recently decreased by 40.36%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for MBIO on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Mustang Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mustang Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.60% of the stock of Mustang Bio is held by insiders.

Percentage Held by Institutions

Only 9.95% of the stock of Mustang Bio is held by institutions.

MBIO Stock Analysis - Frequently Asked Questions

How have MBIO shares performed this year?

Mustang Bio's stock was trading at $1.35 on January 1st, 2024. Since then, MBIO stock has decreased by 87.4% and is now trading at $0.17.
View the best growth stocks for 2024 here.

How were Mustang Bio's earnings last quarter?

Mustang Bio, Inc. (NASDAQ:MBIO) issued its quarterly earnings results on Friday, November, 8th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.09.

When did Mustang Bio's stock split?

Mustang Bio's stock reverse split before market open on Tuesday, April 4th 2023. The 1-15 reverse split was announced on Tuesday, April 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Mustang Bio?

Shares of MBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Mustang Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mustang Bio investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

• Last Earnings: 11/08/2024
• Today: 12/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MBIO
• CUSIP: N/A
• CIK: 1680048
• Web: www.mustangbio.com
• Phone: (781) 652-4500
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $2.00
• High Stock Price Target: $2.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +1,076.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-51,600,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,243.22%
• Return on Assets: -172.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.40
• Quick Ratio: 0.40

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.01 per share
• Price / Book: 17.00

Miscellaneous

• Outstanding Shares: 47,780,000
• Free Float: 47,379,000
• Market Cap: $8.12 million
• Optionable: Not Optionable
• Beta: 1.80